| Recruitment status | Terminated |
| Unique ID issued by UMIN | UMIN000010147 |
| Receipt No. | R000011884 |
| Official scientific title of the study | Urinary biomarkers: potential association with clinical features in patients with contrast-induced nephropathy who undergo percutaneous coronary intervention. |
| Date of disclosure of the study information | 2013/04/01 |
| Last modified on | 2016/07/26 (Ver. 3) |
| Basic information | ||
| Official scientific title of the study | Urinary biomarkers: potential association with clinical features in patients with contrast-induced nephropathy who undergo percutaneous coronary intervention. | |
| Title of the study (Brief title) | Urinary biomarkers for contrast-induced nephropathy in PCI | |
| Region |
|
|
| Condition | |||
| Condition | acute myocardial infarction | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | The aim of this study was to evaluate the utility of urinary L-FABP compared with other urinary parameters for the early detection of post CI-AKI and to evaluate the prognosis among adult patients undergoing PCI. |
| Basic objectives2 | Others |
| Basic objectives -Others | observational study |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | CI-AKI
prognosis |
| Key secondary outcomes | |
| In outcomes field, the entry of just a few words such as "safety" or "efficiency" will not be accepted. Specify the name of outcome measures, including the time when you plan to measure. Usually, only one primary outcome is accepted. Write the other outcomes in "secondary outcomes" field. |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| In interventions field, include the details of interventions, such as duration, amount, and frequency. If the intervention includes prescription or use of medical devices, duration is required. |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Adult patients undergoing PCI in the St. Marianna University School of Medicine were eligible for enrollment.
AMI patients who undergo PCI a couple of times within two weeks. |
|||
| Key exclusion criteria | 1 AMI with fatal condition (Forrester4 arrhythmia, cardiac rupture)
2 Dialysis patient 3 Patients who undergo contrast study within last 14days |
|||
| Target sample size | 200 | |||
| Research contact person | |
| Name of lead principal investigator | Katsuomi Matsui |
| Organization | St. Marianna University School of Medicine |
| Division name | Department of Nephrology and Hypertension, Internal Medicine |
| Address | 2-16-1 Sugao, Miyamae-Ku, Kawasaki 216-8511, Japan |
| TEL | 044-977-8111 |
| m.katsuomi@marianna-u.ac.jp | |
| Public contact | |
| Name of contact person | Katsuomi Matsui |
| Organization | St. Marianna University School of Medicine |
| Division name | Department of Nephrology and Hypertension, Internal Medicine |
| Address | 2-16-1 Sugao, Miyamae-Ku, Kawasaki 216-8511, Japan |
| TEL | 044-977-8111 |
| Homepage URL | |
| m.katsuomi@marianna-u.ac.jp | |
| Sponsor | |
| Institute | St. Marianna University School of Medicine |
| Institute | |
| Department | |
| Sponsor means an organization that is responsible for plan, deployment and report of the research including funding management. It doesn't mean funding agency". Therefore, all clinical trial should have the one. |
| Funding Source | |
| Organization | None |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Terminated | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | a |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000011884 |